New York, USA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Rich Insights into the Opioid Dependence Clinical Trial Analysis Featuring 25+ Companies and Therapies | DelveInsight
The global opioid use disorder market is being driven by the rising cases of opioid addiction. The number of individuals suffering from Opioid addiction has substantially increased, which has led pharmaceutical companies to develop novel therapies. Pipeline therapies focus on reformulations and novel mechanisms of action to combat opioid addiction.
DelveInsight’s 'Opioid Dependence Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline opioid dependence therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the opioid dependence pipeline domain.
Key Takeaways from the Opioid Dependence Pipeline Report
- DelveInsight’s opioid dependence pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for opioid dependence treatment.
- Key opioid dependence companies such as Sen Jam Pharmaceutical, Mindmed, Emergent BioSolutions, Opiant Pharmaceuticals, ATAI Life Sciences, Aphios, Inventage Lab Inc., Trevena Inc., Foresee Pharmaceuticals Co., Ltd, DemeRx, AphioTx Inc., Lyndra Therapeutics, AstraZeneca, Orexo AB, Alar Pharmaceuticals, Ensysce biosciences, Gilgamesh Pharmaceuticals, Indivior, Cerevel Therapeutics, BioCorRx, Kinoxis Therapeutics, Aptinyx, and others are evaluating new drugs for opioid dependence to improve the treatment landscape.
- Promising opioid dependence pipeline therapies in various stages of development include SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Cannabidiol, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, APH-1501, IVL3004, TRV734, DMX-1002, FP-004, DMX-NB1, DMX-IB1, LYN-014, LYN-013, AZD4041, OX124, OX125, ALA-1000, ALA-1300, ALA-2000, GM-300X, SBS-226, CVL-354, BICX104, KNX100, NYX-783, and others.
- In December 2022, the US Food and Drug Administration (FDA) accepted the resubmitted New Drug Application (NDA) for Brixadi (buprenorphine) extended-release weekly and monthly subcutaneous injection for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
- Through a collaboration with the National Institute on Drug Abuse (NIDA), Trevena is developing TRV734 for use in medication-assisted therapy for the treatment of opioid use disorder. Similar to current standard treatment options, it targets the mu receptor, but with an optimized mechanism of action that preferentially engages the signaling pathway responsible for therapeutic effect, with reduced activation of the signaling pathway responsible for mu receptor-mediated adverse effects.
- LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD). The capsule is expected to achieve this through a novel design that will provide extended gastric residence, controlled, steady drug release and timely passage into the gastrointestinal tract. In July 2021, LYN-014 received Fast Track designation (FTD) from the US Food and Drug Administration (FDA).
- In November 2022, Aptinyx Inc. announced the finalization of a grant, issued to researchers at Yale University School of Medicine, funding the research and development of NYX-783 for the treatment of OUD. The $5.6 million grant was awarded under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, administered by the National Institute on Drug Abuse (NIDA). The first clinical study funded by the grant will be a randomized, double-blind, placebo-controlled, Phase I drug-drug interaction study to assess the safety, tolerability, and pharmacokinetics of NYX-783 in combination with oxycodone in individuals who use opioids.
Request a sample and discover the recent advances in opioid dependence treatment drugs @ Opioid Dependence Pipeline Report
The opioid dependence pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage opioid dependence drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the opioid dependence clinical trial landscape.
Opioid Dependence Overview
Opioid use disorder is defined as the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, including over 2.1 million in the United States, and opioids are responsible for over 120K deaths each year. In the United States, there are as many opioid users as there are patients with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy. The American Psychiatric Association DSM-5 defines opioid use disorder as the desire to obtain and use opioids despite social and professional consequences.
Heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone are examples of opioids. Opioid use disorder is characterized by an overwhelming desire to use opioids, increased opioid tolerance, and withdrawal symptoms when the drugs are stopped. Opioid use disorder includes both dependence and addiction, with addiction being the most severe form of the disorder. The disease is treated with opioid replacement therapy, which uses buprenorphine or methadone to reduce morbidity and mortality.
Find out more about opioid dependence treatment drugs @ Drugs for Opioid Dependence Treatment
A snapshot of the Opioid Dependence Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| OX124 | Orexo AB | Phase III | Opioid mu receptor antagonists | Intranasal |
| Cannabidiol | Jazz Pharmaceuticals | Phase II | Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators | |
| DMX-1002 | DemeRx/ATAI Life Sciences | Phase I/II | Excitatory amino acid antagonists; NMDA receptor antagonists; Opioid receptor antagonists | Oral |
| KUR-101 | ATAI Life Sciences | Phase I | Opioid receptor modulators | Oral |
| INDV-2000 | Indivior | Phase I | Orexin receptor type 1 antagonists | Oral |
| LYN-014 | Lyndra Therapeutics | Phase I | Nicotinic receptor antagonists | Oral |
| AZD4041 | AstraZeneca | Phase I | Orexin receptor type 1 antagonists | Oral |
| SJP 006 | Sen Jam Pharmaceutical | Preclinical | NA | Oral |
| FP-004 | Foresee Pharmaceuticals | Preclinical | Opioid receptor agonists | Subcutaneous |
| GM-300X | Gilgamesh Pharmaceuticals | Preclinical | NA | NA |
Learn more about the emerging opioid dependence pipeline therapies @ Opioid Dependence Clinical Trials
Opioid Dependence Therapeutics Assessment
The opioid dependence pipeline report proffers an integral view of opioid dependence emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Opioid Dependence Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous
- Therapeutics Assessment By Molecule Type: Small molecule, Cell Therapy, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Opioid mu receptor antagonists, Excitatory amino acid antagonists; NMDA receptor antagonists; Opioid receptor antagonists, Alpha3beta4 nicotinic receptor antagonists, Opioid receptor modulators, Orexin receptor type 1 antagonists, Nicotinic receptor antagonists, Opioid receptor agonists, Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
- Key Opioid Dependence Companies: Medicenna Therapeutics, Tarveda Therapeutics, Sen Jam Pharmaceutical, Mindmed, Emergent BioSolutions, GW Pharmaceuticals, Opiant Pharmaceuticals, ATAI Life Sciences, C4X Discovery, and others.
- Key Opioid Dependence Pipeline Therapies: SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Cannabidiol, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, and others.
Dive deep into rich insights for new drugs for opioid dependence treatment; visit @ Opioid Dependence Medications
Table of Contents
| 1. | Opioid Dependence Pipeline Report Introduction |
| 2. | Opioid Dependence Pipeline Report Executive Summary |
| 3. | Opioid Dependence Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Opioid Dependence Clinical Trial Therapeutics |
| 6. | Opioid Dependence Pipeline: Late Stage Products (Pre-registration) |
| 7. | Opioid Dependence Pipeline: Late Stage Products (Phase III) |
| 7.1 | OX124: Orexo AB |
| 8. | Opioid Dependence Pipeline: Mid Stage Products (Phase II) |
| 8.1 | Cannabidiol: Jazz Pharmaceuticals |
| 9. | Opioid Dependence Pipeline: Early Stage Products (Phase I) |
| 9.1 | LYN-014: Lyndra Therapeutics |
| 10. | Opioid Dependence Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Opioid Dependence Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Opioid Dependence Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the opioid dependence pipeline therapeutics, reach out @ Opioid Dependence Treatment Drugs
Related Reports
Opioid Dependence Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid dependence companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, ATAI Life Sciences, C4X Discovery, among others.
Opioid Dependence Epidemiology Forecast
Opioid Dependence Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted opioid dependence epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Opioid-Related Disorder Pipeline
Opioid-Related Disorder Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key opioid-related disorder companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, among others.
Opioid Withdrawal Syndrome Pipeline
Opioid Withdrawal Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key opioid withdrawal syndrome companies, including Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, among others.
Opioid-Related Disorder Market
Opioid-Related Disorder Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid-related disorder companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, among others.
Opioid Withdrawal Syndrome Market
Opioid Withdrawal Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid withdrawal syndrome companies, including Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
